Navigation Links
Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting

Surfaxin Phase 2 BPD Clinical Data Selected and Presented as Platform Presentation

Aerosurf Utilizing Chrysalis Aerosol-Generator Technology Demonstrates Optimal Functional Activity

WARRINGTON, Pa., May 8, 2007 (PRIME NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) announced that results from its previously completed Phase 2 clinical trial of Surfaxin(r) (lucinactant intratracheal suspension) for the prevention and treatment of Bronchopulmonary Dysplasia (BPD) were selected and presented as a platform presentation at the Pediatric Academic Societies' (PAS) Annual Meeting in Toronto, Canada. Also presented at PAS were data regarding Discovery's novel aerosolized KL-4 surfactant, Aerosurf(tm) (lucinactant for inhalation). The Pediatric Academic Societies' annual meeting is internationally recognized as the largest, most relevant medical meeting dedicated to pediatric critical care research. These data were presented for the first time to the medical community.

Phase 2 Clinical Trial of Surfaxin(r) for the Prevention and Treatment of BPD

Carl Bose, MD, Director of Neonatology and Professor of Pediatrics at University of North Carolina and Chairman of the Discovery BPD Clinical Study Steering Committee, presented an overview of key trial data. These data suggest that Surfaxin, when administered beyond the standard acute Respiratory Distress Syndrome (RDS) treatment period, may represent a novel therapeutic option for infants at risk for developing BPD. BPD is a chronic, debilitating lung disease affecting premature infants who survive treatment for RDS. Presently, there are no approved pharmaceutical therapies for BPD.

Surfaxin was shown to be generally safe and well-tolerated. Top-line results demonstrated that infants treated with up to five incremental standard doses of Surfaxin experienced:

* a lower incidence of death or BPD,

* a higher survival rate thr
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Discoverys KL-4 Surfactant Technology Demonstrates Novel Anti-Inflammatory Properties
3. Major Discovery Raises Prospect of Better Patient Care By Improving Platelet Life Span
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
7. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
10. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
11. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
Post Your Comments:
(Date:10/30/2014)... NOTTINGHAM, United Kingdom , Oct. 30, 2014 /PRNewswire/ ... Inc., (Nasdaq: CBRX ) and ... assist drug developers with improved efficiency during clinical development ... San Diego next week. This ... enabling technologies platform, which it launched earlier this month. ...
(Date:10/30/2014)... , Oct. 30, 2014   BioLife Solutions ... developer, manufacturer and marketer of proprietary clinical grade ... and precision thermal shipping products for cells ... quarter 2014 financial results will be released on Thursday, ... a conference call and live webcast at 1:30 p.m. ...
(Date:10/30/2014)...   Auxilium Pharmaceuticals , Inc. (NASDAQ: ... company, today announced financial results for the third ... important corporate, commercial, regulatory and clinical development updates ... very pleased with the continued momentum and strong ... portfolio this quarter, especially the XIAFLEX franchise, which ...
Breaking Medicine Technology:Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3BioLife Solutions to Report Financial Results for Third Quarter 2014 and Provide Business Update on November 6, 2014 2Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 2Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 3Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 4Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 5Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 6Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 7Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 8Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 9Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 10Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 11Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 12Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 13Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 14Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 15Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 16Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 17Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 18Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 19Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 20Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 21Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 22
... and Progressive Form of Inflammatory Spinal Arthritis Receiving Monthly Golimumab ... ... BOSTON, Nov. 7 More than half of patients receiving,monthly ... experienced significant and sustained improvements in the signs and,symptoms of active ...
... of Trial Volunteers Must Remain Paramount Concern, SEATTLE, ... the following statement today from Executive,Director Mitchell Warren in ... AIDS vaccine study by Merck & Co., the US ... HIV Vaccine Trials Network,(HVTN) at a public forum at ...
Cached Medicine Technology:New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings 2New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings 3New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings 4New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings 5New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings 6New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings 7AIDS Vaccine Advocacy Coalition Calls for AIDS Vaccine Field to Work Together to Analyze STEP Study Data and Determine Best Course to Move Forward 2AIDS Vaccine Advocacy Coalition Calls for AIDS Vaccine Field to Work Together to Analyze STEP Study Data and Determine Best Course to Move Forward 3
(Date:10/30/2014)... WHAT: , A mathematical model developed by NIH grantees ... daily to prevent HIV infection via vaginal sex, whereas ... HIV infection via anal sex. This finding helps explain ... or PrEP, in women failed to show efficacy. Participants ... trials of Truvada and tenofovir (another antiretroviral) for HIV ...
(Date:10/30/2014)... San Diego, Calif. (PRWEB) October 30, 2014 ... no longer mutually exclusive concepts in the medical-grade ... focusing on the development of uniquely potent topical ... Skin Health System ( http://www.RefinitySkinScience.com ) with patented ... highest available glycolic acid concentrations (50% and 70%) ...
(Date:10/30/2014)... By Steven Reinberg ... -- Giving hormone therapy to men with prostate cancer who ... dying from a heart-related cause, a new study suggests. , , ... It,s used in prostate cancer to reduce levels of male ... the study. And, in the current research, this hormone therapy ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 Horse ... therapeutic horseback riding to special needs individuals in the ... on Saturday, November 15 from 10-2:00 p.m. at Bailey's ... is open to the public and is designed to ... , Admission to the HSS Round-Up is free. Ticket ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 The annual ... (NAMS) came to a close on Saturday, October 18th, ... the Society’s inception in 1989. NAMS is North America’s ... quality of life of all women during midlife and ... With over 2,000 physicians and thought leaders from fields ...
Breaking Medicine News(10 mins):Health News:Model by NIH grantees explains why HIV prevention dosing differs by sex 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 3Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 4Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 2Health News:Hormone Therapy May Up Heart-Related Deaths in Some Prostate Cancer Patients 3Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 2Health News:Highlights from The North American Menopause Society 25th Annual Meeting 3
... at Rice University have discovered that intense pressure -- ... half-mile beneath the ocean,s surface -- stimulates cartilage cells ... properties of natural cartilage. The new method, which requires ... of arthritis sufferers. , "This tissue-engineering method holds promise ...
... honoured with a Commendation in this year,s Premier,s Award ... Fellow and was previously a PhD student in WEHI,s ... Priscilla with the Commendation at a ceremony at Government ... on two key aspects of cancer biology. First, identifying ...
... once-a-week participation was associated with improved results , , WEDNESDAY, ... Anonymous offer benefits to adolescents, even if they eventually ... teens enrolled at two treatment centers in California. ... from four to six weeks at the centers, which ...
... societal, and health carerelated issues contribute to disparities in ... to two articles appearing in the July 2008 issue ... The articles indicate that immediate and substantial efforts on ... health care for affected Americans. Such concerted efforts can ...
... Provide Alaska Rural Telecommunication Services for Next ... ... GNCMA ),announced today that it successfully transitioned all of its rural,telecommunication ... Internet, distance education and,telehealth services throughout rural Alaska for the next 14 ...
... from Thomson Reuters to Analyze Promising Drugs Changing Clinical Phase, ... Generics ... ... leading source of intelligent information for businesses and,professionals, has announced the ...
Cached Medicine News:Health News:Cartilage regeneration '20,000 Leagues Under the Sea' 2Health News:Cartilage regeneration '20,000 Leagues Under the Sea' 3Health News:Insights into cancer earn Premier's Award Commendation 2Health News:Alcohol, Drug Counseling Benefits Teens, Too 2Health News:Racial disparities in the outcomes of patients with chronic kidney disease abound 2Health News:Racial disparities in the outcomes of patients with chronic kidney disease abound 3Health News:GCI Successfully Transitions All Traffic to Galaxy 18 Satellite 2Health News:The Scientific Business of Thomson Reuters Publishes Pharma Matters - a Series of Reviews Covering Various Aspects of the Pharmaceutical Pipeline 2Health News:The Scientific Business of Thomson Reuters Publishes Pharma Matters - a Series of Reviews Covering Various Aspects of the Pharmaceutical Pipeline 3
... rotary retracting, self-lubricating design and has a heavy ... construction makes it accurate and incredibly reliable. ,The ... lateral motion is controlled and allows no slop ... lesser designs which can result in 'chatter' and ...
... The new SureCut M3500 Radial Microtome has ... is marvelous, and a range of functions and ... users. Based on years of experience and ... innovative design the SureCut M3500 Microtome will be ...
This is an economical (portable) microtome designed for fast and accurate sectioning. The specimen rise is automatic and accurate with each handle movement. Section thickness from 5 to 40 microns. ...
Honing compound for knife sharpening, 6 grams net...
Medicine Products: